BRUSSELS, April 13, 2011 /PRNewswire/ — New rotigotine data
shown in four poster presentations at the 63rd Annual Meeting of
the American Academy of Neurology (AAN) in Hawaii, U.S.,
highlighted the importance in Parkinson’s disease (PD) of
addressing both motor- and non-motor symptoms, such as sleep. The
data also demonstrated the long-term efficacy and tolerability of
rotigotine and showed that plasma rotigotine levels remained stable
following patch removal and application of a new patch in advanced
Parkinson’s disease.
Treating motor and non-motor symptoms of PD
Post-hoc analyses of the Randomized Evaluation of the 24-hour
Coverage: Efficacy of Rotigotine (RECOVER) study showed only small
correlations between changes in early morning motor and non-motor
symptoms and between severity of nocturnal sleep disturbances and
early morning motor symptoms in patients with Parkinson’s
disease.
“The low correlation between motor and non-motor symptoms,
specifically early morning motor function and night-time sleep
disturbances, has an important bearing on clinical practice. The
analyses suggest that we cannot assume that by treating motor
symptoms we will also improve non-motor symptoms. We need to be
sure to ask patients about all their Parkinson’s symptoms and
address their specific needs, if we are to improve functionality
and well-being,” commented Dr. Todd Swick of the University of
Texas, U.S.
The RECOVER study was a double-blind, placebo-controlled trial
(n=287) that reported significant benefits with rotigotine for both
early morning motor function (Unified Parkinson’s Disease Rating
Scale; UPDRS Part III) and nocturnal sleep disturbances
(Parkinson’s Disease Sleep Scale; PDSS-2), compared with placebo
(p=0.0002 and p<0.0001, respectively).
The new post hoc analyses have shown:
- Small correlations (Pearson correlation coefficients) between
severity of early morning mot‘/>”/>
